

## NRG Scientific Session NRG Oncology Research Review

**Date:** Friday, July 13, 2018  
**Start and End Time:** 8:00 am – 10:00 am  
**Co-Chairs:** Deborah W Bruner, PhD; Elizabeth M Gore, MD; Thomas B Julian, MD (Moderator);  
 and Krishnansu S Tewari, MD

### Learning Objectives:

#### Following this activity, participants will be better able to:

1. Examine the effectiveness of chemotherapy (CT) after local therapy for Isolated Locoregional Recurrence (ILRR).
2. Discuss how to optimize radiation therapy techniques for localized prostate cancer to impact patient outcomes.
3. Distinguish between the use of chemotherapy with and without concurrent BEV, and with concurrent BEV followed by maintenance BEV for advanced stage ovarian carcinoma.
4. Describe 5-year results to understand how potential late events may influence the utility of Stereotactic Body Radiation Therapy (SBRT) in medically inoperable patients with clinically staged early lung cancer.
5. Explain the association between MLH1 expression and survival in patients who underwent resection of pancreatic cancer and received adjuvant chemoradiation.
6. Understand the patient-reported acute toxicity and health-related quality of life (QOL) during treatment with standard pelvic radiation or Intensity-modulated radiation therapy (IMRT) in women with cervical and endometrial cancer.
7. Educate members regarding the Quantitative Imaging Network and its role in the development, validation and application of quantitative image analysis tools for advancement of multi-institutional clinical trials.

### WORKSHOP AGENDA

8:00 – 8:05 am	Welcome	Thomas B Julian, MD
8:05 – 8:15 am	Efficacy of chemotherapy for ER-negative and ER-positive isolated locoregional recurrence of breast cancer: Final analysis of the CALOR Trial.	Irene L Wapnir, MD
8:15 – 8:20 am	Discussant	Ruth O'Regan, MD
8:20 – 8:30 am	NRG Oncology RTOG 0126: A randomized phase III trial comparing standard and dose escalated radiation therapy for patients with intermediate risk prostate cancer.	Jeff Michalski, MD
8:30 – 8:35 am	Discussant	Leonard Gomella, MD
8:35 – 8:45 am	Final Overall Survival (OS) Analysis of an International Randomized Trial Evaluating Bevacizumab (BEV) in the Primary Treatment of Advanced Ovarian Cancer: A NRG Oncology/Gynecologic Oncology Group (GOG) study	Krishnansu S. Tewari, MD (R Burger 1 <sup>st</sup> author)
8:45 – 8:50 am	Discussant	Kathleen Moore, MD
8:50 – 9:00 am	Long-term Results of NRG Oncology RTOG 0236: A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in Medically Inoperable Stage I Non-Small Cell Lung Cancer.	Robert Timmerman, MD
9:00 – 9:05 am	Discussant	Clifford Robinson, MD
9:05 – 9:15 am	Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704.	Chandan Guha, MD (Y Lawrence 1 <sup>st</sup> author)
9:15 – 9:20 am	Discussant	Terrance Williams, MD
9:20 – 9:30 am	Patient-reported toxicity during pelvic IMRT: NRG Oncology-RTOG 1203	Ann H Klopp, MD
9:30 – 9:35 am	Discussant	Patricia Ganz, MD
9:35 – 9:50 am	Quantitative Imaging Network (QIN) presentation	John Buatti, MD
9:50 – 10:00 am	Q&A	